PUBLISHER: FirstWord Group | PRODUCT CODE: 1549554
PUBLISHER: FirstWord Group | PRODUCT CODE: 1549554
Ovarian Cancer - KOL Insight
KOLs critically assess the evolving landscape of ovarian cancer treatment, including the sustained importance of PARP inhibitors like Lynparza, emerging competition from antibody-drug conjugates (ADCs), and the future potential of novel therapies such as saruparib and next-generation PARPis. Explore the promising outcomes of ImmunoGen's Elahere in platinum-resistant settings and the cautious optimism surrounding AstraZeneca's Enhertu, among others. However, significant challenges remain, particularly for immunotherapy combinations and certain experimental treatments.
Key brands covered in this report:
|
|
Companies:
Novartis, Lilly, Roche, GSK, AstraZeneca, Pfizer, Merck, Merck & Co., Bristol Myers Squibb, Genentech, Daiichi Sankyo, ImmunoGen, Menarini, Johnson & Johnson Innovative Medicine, Merck Group, Corcept Therapeutics, Ono Pharmaceutical, Alkermes, Zymeworks, OncoQuest, Gradalis, Verastem Oncology, Sutro Biopharma, Genelux, pharma&, Antengene, Artios Pharma, Karyopharm Therapeutics, Klus Pharma, Zentalis Pharmaceuticals.
Key questions answered:
- What are the current backbone treatments for ovarian cancer, and what are their pros and cons?
- How does the medical community view PARP inhibitors like Lynparza, Rubraca, and Zejula in terms of efficacy, tolerability, and ease of use, and how might their usage change?
- Which recent or ongoing clinical trials could significantly impact prescribing trends, and what will their results mean for the future of ovarian cancer treatment?
- What must emerging targeted therapies demonstrate to become the preferred treatments for specific patient segments, and are they likely to meet these criteria?
- Which pipeline products show the most promise, and how will they affect current market players?
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Marketed products
- PARPis
- Insights for the PARPis (Lynparza, Rubraca, Zejula)
- Lynparza (olaparib; AstraZeneca/Merck & Co.)
- Rubraca (rucaparib; Pharma& Schweiz)
- Zejula (niraparib; GSK)
- ADC/tubulin/DNA topoisomerase I inhibitors
- Insights for the ADC/tubulin/DNA topoisomerase I inhibitors
- Elahere (mirvetuximab soravtansine; ImmunoGen)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
Pipeline products
- Immune checkpoint inhibitors (ICI)
- Insights for the ICI class
- Bavencio (avelumab; Merck Group)
- Imfinzi (durvalumab; AstraZeneca)
- Jemperli (dostarlimab; GSK)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono)
- Tecentriq (atezolizumab; Roche)
- Immunostimulants
- Insights for the immunostimulants
- Oregovomab (anti-idiotype mAb; OncoQuest)
- Therapeutic vaccines
- Insights for the therapeutic vaccines
- Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation)
- Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis)
- Next-generation ADCs
- Insights for the next-generation ADCs
- STRO-002 (luveltamab tazevibulin; Sutro Biopharma)
- R-DXd (raludotatug deruxtecan; Daiichi Sankyo/Merck & Co.)
- Other late-stage modalities
- Insights on MAP/RAF/FA kinase inhibitors
- VS 6766/VS 6063 (avutometinib/defactinib; Verastem Oncology)
- Glucocorticoid receptor antagonists
- CORT-125134 (relacorilant; Corcept Therapeutics)
- Mid and early-stage modalities
- Next-generation ADCs and other MOAs
- ART6043 (Artios Pharma)
- AZD-5305 (saruparib; AstraZeneca)
- AZD 6738 (ceralasertib; AstraZeneca)
- AZD 8205 (AstraZeneca)
- IMGN 151 (ImmunoGen)
- KP-2638/ZN-c3 (azenosertib; Zentalis Pharmaceuticals)
- MK-2870 (sacituzumab tirumotecan; Klus Pharma/Merck & Co)
- Nexpovio/Xpovio (selinexor; Antengene/Karyopharm Therapeutics/Menarini)
- Rina-S (rinatabart sesutecan; ProfoundBio)
- Verzenio/Verzenios (abemaciclib; Eli Lilly and Company)
- ZW 191 (Zymeworks)
Appendix
- KOL details
- KOLs from the US
- KOLs from Europe
News
